Abstract
Radiotherapy for brain metastases has evolved tremendously over the past four decades, allowing for improved intracranial control of disease with reduced neurotoxicity. The main technological advance was provided by volumetric modulated arc therapy (VMAT), a computer-controlled delivery method that has opened the door for single-isocenter multi-metastases stereotactic radiosurgery (SRS) and hippocampal avoidance whole brain radiation therapy (HA-WBRT). Other notable advances have occurred in the combination of immune checkpoint inhibitors (ICI) and radiosurgery. When these two modalities are combined in the proper sequence (within 30 days from each other), it provides promising results in the treatment of intracranial metastases from melanoma. There is emerging evidence of a synergistic interaction between ICI and SRS, providing better intracranial tumor control and lengthening the survival of patients afflicted by this common complication of cancer.
Similar content being viewed by others
References
Nichols EM, Patchell RA, Regine WF, Kowk Y (2013) Palliation of brain and spinal cord metastases. In: Halperin EC, Wazer DE, Perez CA, Brady LW (eds) Perez and brady’s principles and practice of radiation oncology, 6th edn. Lippincott Williams & Wilkins, Philadelphia, pp 1765–1772
Usuki KY, Milano MT, David M, Okunieff P (2015) Metastatic disease: bone, spinal cord, brain, liver, and lung. In: Gunderson Leonard L, Tepper Joel E (eds) Clinical radiation oncology, 4th edn. Elsevier Health Sciences, Philadelphia, pp 443–445
Patchell RA, Tibbs PA, Regine WF, Dempsey RJ, Mohiuddin M, Kryscio RJ, Markesbery WR, Foon KA, Young B (1998) Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA. 280(17):1485–9
Andrews DW, Scott C, Sperduto P, Curran W et al (2004) Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. The Lancet 363(9422):1665–1672
Aoyama H, Shirato H, Tago M et al (2006) Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 295(21):2483–2491
Kocher M, Soffietti R, Abacioglu U, Villa S, Fauchon F, Baumert BG, Hassel MB et al (2011) Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952–26001 study. J Clin Oncol 29(2):134
Borgelt B, Gelber R, Kramer S, Brady LW, Chang CH, Davis LW, Hendrickson FR et al (1980) The palliation of brain metastases final results of the first two studies by the radiation therapy oncology group. Int J Radiat Oncol *Biol*Phys 6(1):1–9. https://doi.org/10.1016/0360-3016(80)90195-9
Brown PD, Pugh S, Laack NN, Wefel JS, Khuntia D, Meyers C, Kavadi V et al (2013) Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro Oncol 15(10):1429–1437
Gondi V, Pugh SL, Tome WA, Caine C, Corn B, Kanner A, Konski AA et al (2014) Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. J Clin Oncol 32(34):3810
Brown PD, Gondi V, Pugh S, Tome WA, Wefel JS, Armstrong TS, Grosshans D et al (2020) Hippocampal avoidance during whole-brain radiotherapy plus memantine for patients with brain metastases: phase III trial NRG oncology CC001. J Clin Oncol 38(10):1019–1029
Patchell RA, Tibbs PA, Walsh JW et al (1990) A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322(8):494–500
Vecht CJ, Haaxma-Reiche H, Noordijk EM, Padberg GW, Voormolen JH, Hoekstra FH, Brand R et al (1993) Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery. Ann Neurol 33(6):583–590
Mintz AH, Kestle J, Rathbone MP, Gaspar L, Hugenholtz H, Fisher B, Levine M et al (1996) A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer 78(7):1470–1476
Sperduto PW, Song CW (2016) Radiobiology of stereotactic radiosurgery and stereotactic ablative radiotherapy. In: Khan FM, Gibbons JP, Sperduto PW (eds) Khan’s treatment planning in radiation oncology, 4th edn. Wolters Kluwer, Philadelphia, pp 355–359
Mahajan A, Ahmed S, McAleer MF, Weinberg JS, Li J, Brown P, McGovern S et al (2017) Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. Lancet Oncol 18(8):1040–1048
Sahgal A, Aoyama H, Kocher M, Neupane B, Collette S, Tago M, Chang EL et al (2015) Phase 3 trials of stereotactic radiosurgery with or without whole-brain radiation therapy for 1 to 4 brain metastases: individual patient data meta-analysis. Int J Radiat Oncol*Biol*Phys 91(4):710–717
Yamamoto M, Serizawa T, Shuto T, Akabane A, Higuchi Y, Kawagishi J, Nagano O et al (2014) Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol 15(4):387–395
Duggan DM, Coffey C (1998) Small photon field dosimetry for stereotactic radiosurgery. Med Dosim 23(3):153–159
Solberg TD, Boedeker KL, Fogg R, Selch MT, DeSalles AA (2001) Dynamic arc radiosurgery field shaping: a comparison with static field conformal and noncoplanar circular arcs. Int J Radiat Oncol*Biol*Phys 49(5):1481–1491
Unkelbach J (2016) Intensity-modulated radiation therapy: photons. In: Khan FM, Gibbons JP, Sperduto PW (eds) Khan’s treatment planning in radiation oncology, 4th edn. Wolters Kluwer, Philadelphia, pp 122–149
Clark GM, Popple RA, Young PE, Fiveash JB (2010) Feasibility of single-isocenter volumetric modulated arc radiosurgery for treatment of multiple brain metastases. Int J Radiat Oncol*Biol*Phys 76(1):296–302
Hellman S, Weichselbaum RR (1995) Oligometastases. J Clin Oncol 13(1):8–10
Uppal A, Ferguson MK, Posner MC, Hellman S, Khodarev NN, Weichselbaum RR (2014) Towards a molecular basis of oligometastatic disease: potential role of micro-RNAs. Clin Exp Metas 31(6):735–748
Hu X, Hui Y, Zhenget Y et al (2020) Immune checkpoint inhibitors and survival outcomes in brain metastases: a time series-based meta-analysis. Front Oncol 10:2180. https://doi.org/10.3389/fonc.2020.564382
Wilson EH, Weninger W, Hunter CA (2010) Trafficking of immune cells in the central nervous system. J Clin Investig 120(5):1368–1379
Finkelstein SE, Timmerman R, McBride WH, Schaue D, Hoffe SE, Mantz CA, Wilson GD (2011) The confluence of stereotactic ablative radiotherapy and tumor immunology. Clin Dev Immunol 2011:439752. https://doi.org/10.1155/2011/439752
Blank C, Gajewski TF, Mackensen A (2005) Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother 54(4):307–314
Seung SK, Curti BD, Crittenden M, Walker E, Coffey T, Siebert JC, Urba WJ et al (2012) Phase 1 study of stereotactic body radiotherapy and interleukin-2–tumor and immunological responses. Sci Transl Med 4(137):13774
Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, Sedrak C et al (2012) Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 366(10):925–931
Okwan-Duodu D, Pollack BP, Lawson D, Khan MK (2015) Role of radiation therapy as immune activator in the era of modern immunotherapy for metastatic malignant melanoma. Am J Clin Oncol 38(1):119–125
Skrepnik T, Sundararajan S, Cui H, Stea B (2017) Improved time to disease progression in the brain in patients with melanoma brain metastases treated with concurrent delivery of radiosurgery and ipilimumab. Oncoimmunology 6(3):e1283461. https://doi.org/10.1080/2162402X.2017.1283461
Lehrer EJ, Peterson J, Brown PD, Sheehan JP, Quiñones-Hinojosa A, Zaorsky NG, Trifiletti DM (2019) Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: an international meta-analysis of individual patient data. Radiother Oncol 130:104–112
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Ho, QA., Stea, B. Innovations in radiotherapy and advances in immunotherapy for the treatment of brain metastases. Clin Exp Metastasis 39, 225–230 (2022). https://doi.org/10.1007/s10585-021-10104-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10585-021-10104-z